Skip to main content
Clinical Trials/NL-OMON53381
NL-OMON53381
Recruiting
Phase 4

se of mechaNical left ventricuLar unlOADing in Complex Higher-risk Indicated Procedures - UNLOAD CHIP

Amsterdam UMC0 sites98 target enrollmentTBD

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Coronairy artery disease
Sponsor
Amsterdam UMC
Enrollment
98
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Interventional

Investigators

Sponsor
Amsterdam UMC

Eligibility Criteria

Inclusion Criteria

  • \- Age 18 or older \- Multidisciplinary heart team consensus for MCS facilitated
  • PCI AND \- Stabilized after admission for ACS/NSTEMI OR ADHF (SCAI A\-B) AND \-
  • LVEF \<30% AND \- Complex left main disease ( requiring debulking techniques,
  • 2\-stent etc,) OR equivalent (ostial LAD and RCX) OR last remaining vessel
  • (native) with likely prolonged procedural ischemia

Exclusion Criteria

  • \- Contraindications for Pulsecath IVAC2L: a. moderate\-severe aortic
  • regurgitation b. known presence of an LV thrombus (contrast echo/MRI) c. aortic
  • valve prosthesis d. severe aortic valve stenosis e. peripheral arterial disease
  • that would preclude placement of the PulseCath iVAC2L device \- Cardiogenic
  • shock defined as either SCAI CSWG stage C\-E \- Patient is intubated and
  • mechanically ventilated \- Stroke \<3 months \- Major bleeding event \<3 months \-
  • History of bleeding diathesis or known coagulopathy (including heparin\-induced
  • thrombo\-cytopenia), any recent GU or GI bleed, or will refuse blood
  • transfusions. \- Chronic kidney disease with eGFR \<25\. \- Pregnancy, or suspected
  • thereof. \- BMI \> 35

Outcomes

Primary Outcomes

Not specified

Similar Trials